Nuclear Molecular and Theranostic Imaging for Differentiated Thyroid Cancer

Area of Science:

• Nuclear medicine
• Molecular imaging
• Theranostics

Background:

• Traditional nuclear medicine is evolving with molecular imaging and theranostics.
• The role of scintigraphy in differentiated thyroid cancer (DTC) diagnostics and therapy is often underestimated.
• A paradigm shift is occurring, moving away from radioactive iodine (RAI) imaging in DTC management, supported by recent guidelines.

Purpose of the Study:

• To review the clinical utility and controversies of scintigraphy in differentiated thyroid cancer (DTC).
• To highlight the importance of understanding disease pathophysiology and imaging methodologies for optimal DTC management.
• To discuss the evolving role of nuclear imaging in light of technological advancements.

Main Methods:

• Review of current literature on scintigraphy in differentiated thyroid cancer (DTC).
• Analysis of clinical information provided by scintigraphy for disease management.
• Discussion of advancements in radiotracer and imaging technology.

Main Results:

• Scintigraphy provides valuable clinical information for DTC patient care that is currently underestimated.
• Significant developments in radiotracer and imaging technology enhance the understanding of tumor biology.
• The field is rapidly evolving with new diagnostic and therapeutic techniques emerging.

Conclusions:

• A comprehensive understanding of DTC pathophysiology and imaging is crucial for optimal patient care.
• Scintigraphy remains a relevant tool in DTC management, despite evolving trends.
• Nuclear imaging applications will continue to adapt and play a vital role in the changing landscape of DTC treatment.